Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
By Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael B. Streiff, and John F. Andersen
Heparin-induced thrombocytopenia (HIT) involves platelet activation by PF4/anti-PF4 complexes.
This study identifies glycoprotein VI (GPVI) as a receptor for these complexes, enhancing PF4 binding (Kd ≈ 30–100 nM) and platelet aggregation via FcγRIIA.
GPVI blockade (anti-GPVI antibodies, ACT017) suppressed activation, while AlphaFold modeling revealed electrostatic interactions between GPVI and PF4/IgG.
These findings position GPVI as a potential therapeutic target in HIT.”
Read the full article in JTH.
Article: Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
Authors: Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael Streiff, John Andersen

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
